Enzymatic drug release cascade from polymeric prodrug nanoassemblies enables targeted chemotherapy.

Cancer drug delivery systems often suffer from premature drug leakage during transportation and/or inefficient drug release within cancer cells. We present here a polymeric prodrug nanoassembly that addresses these problems simultaneously. This nanoassembly comprises a polymeric prodrug with novel trivalent phenylboronate moieties for drug conjugation via ether linkages, as well as β -lapachone (Lapa). While the ether linkage enables nearly no drug release under physiological conditions, the Lapa molecules can induce the reactive oxygen species (ROS) burst specifically in cancer cells via NAD(P)H: quinone oxidoreductase-1 catalysis, which triggers the cleavage of the ether bonds and thus cascade amplification drug release in cancer cells. As a result, the nanoassemblies exhibit much higher cytotoxicity against cancer cells than normal cells, and also increased therapeutic efficacy and reduced side effects compared to the clinically used irinotecan. We anticipate that this strategy can be applied to other drug delivery platforms to enable more precise drug release. A novel polyprodrug of 7-ethyl-10-hydroxycamptothecin, bearing an ether-bridged trivalent phenylboronate moiety, co-assemble with β-lapachone to form stable micelles, achieving cancer cell-specific NQO1-triggered cascade amplification drug release. [Display omitted] [ABSTRACT FROM AUTHOR]